Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HRS 2016 ROUND-UP: Medtronic Unveils New “Extravascular ICD”

Executive Summary

The 2016 Heart Rhythm Society’s Annual Scientific Sessions were held in San Francisco on May 4-7 and featured over 250 educational sessions on cardiac rhythm management and electrophysiology, including presentations of new clinical data from medical device trials. Here are some of the highlights.

You may also be interested in...



Medtronic’s Extravascular ICD Stops Ventricular Arrhythmias In Pilot Trial

In a 21-patient first in-human pilot trial, Medtronic’s Extravascular Implantable Cardioverter Defibrillator (EV ICD) system successfully terminated induced ventricular arrhythmias in 89.5% of patients and achieved pacing capture in 95% of patients.

HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis Of Contact-Force Catheter; LuxCath's OmniView; More Micra Results

The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.

MRI Labeling For Boston Scientific's Emblem MRI S-ICD Approved By US FDA

Boston Scientific cardiac rhythm management has been struggling to compete with MRI-compatible devices from rival Medtronic.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel